C5 and myeloid sarcoma: Beyond Anti-AQP4+ NMOSD and generalized myasthenia gravis, where the C5-inhibitor antibody eculizumab has been FDA-approved for treatment, inhibition of the complement system has also been explored in multiple other neurodegenerative and neuroinflammation models, including AD and MS.